Skip Navigation


European Heart Journal Advance Access originally published online on October 25, 2005
European Heart Journal 2005 26(23):2479-2481; doi:10.1093/eurheartj/ehi553
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/23/2479    most recent
ehi553v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Svilaas, T.
Right arrow Articles by Zijlstra, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svilaas, T.
Right arrow Articles by Zijlstra, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

The role of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST elevation myocardial infarction

Tone Svilaas*, Iwan C.C. van der Horst and Felix Zijlstra

Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands

* Corresponding author. Tel: +31 50 3610444; fax: +31 50 3611347. E-mail address: t.svilaas@thorax.umcg.nl

This editorial refers to ‘Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study’{dagger} by The Admiral Investigators on page 2520

The first 10% of the full text of this article appears below.

The administration of glycoprotein IIb/IIIa inhibitors is considered to provide additional benefit to mechanical reperfusion in the treatment of patients with ST elevation myocardial infarction and is included as a class-IIa recommendation in the Guidelines for Percutaneous Coronary Intervention of the European Society of Cardiology.1 Glycoprotein IIb/IIIa inhibitors block the surface receptor, which is a member of the integrin superfamily of membrane-bound adhesion molecules. Binding to the major adhesive proteins, fibrinogen and von Willebrand, occurs due to a conformational change of the glycoprotein IIb/IIIa receptor. This final step in platelet aggregation is blocked by the glycoprotein IIb/IIIa inhibitors. Other effects of the glycoprotein IIb/IIIa receptor are interference with thrombus formation, including induction of platelet disaggregation, and reduced clot retraction. Inhibitors developed and used in routine clinical practice include abciximab, the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study
The ADMIRAL Investigators
EHJ 2005 26: 2520-2523. [Abstract] [FREE Full Text]